GSK plc announced that on May 19, 2025, Japan approved Blenrep combinations for treating relapsed/refractory multiple myeloma, showcasing superior effectiveness over current treatments in pivotal trials. This marks the second major approval for Blenrep, expected to impact patient care significantly as more approvals are anticipated in 2025.